Introduction: Direct oral anticoagulants (DOACs) have seen rapid uptake for the prevention of stroke associated with non-valvular atrial fibrillation (NVAF). It is unclear whether use of DOACs represents direct therapeutic substitution over warfarin or if this coincides with an increase in overall treatment rates. This study sought to describe the difference in oral anticoagulant (OAC) use in the pre-DOAC and post-DOAC eras.
Methods: Incident cases of NVAF were identified from the Truven Marketscan database during the years 2005-2009 ('pre-DOAC') and 2013 ('post-DOAC'). Demographic and clinical characteristics were compared for the overall cohorts and among those who did and did not receive OAC in both time periods. OAC treatment was observed by stroke (CHA2DS2-VASc) and bleed risk (HAS-BLED) scores. Logistic regression was used to compare the individual characteristics associated with OAC use between the study periods.
Results: During the pre- and post-DOAC eras, 105,610 and 11,992 NVAF patients were identified. OAC treatment increased from 42.2 to 54.0 % (absolute change 11.8 %, relative change 28.0 %) from the pre- to post-DOAC periods without meaningful differences between the populations. Larger relative increases in OAC treatment were observed for those at high risk of stroke (33.9 % increase) and for those with moderate (30.4 % increase) to high risk (28.6 % increase) of bleed. Other than time period of diagnosis, no patient characteristics differed between those treated with OACs in the pre and post periods.
Conclusions: There has been an overall increase in OAC use in the NVAF population, attributable to both favorable randomized trial results and aggressive marketing of DOACs in the USA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40266-016-0369-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent Systemic Inflammation Is Associated With Bleeding Risk in Atrial Fibrillation Patients.
Circ J
February 2020
Department of Cardiology, Osaka Police Hospital.
Background: This study investigated the impact of systemic inflammation on bleeding risk in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOAC).
Methods and results: We conducted a single-center prospective registry of 2,216 NVAF patients treated with DOAC: the DIRECT registry (UMIN000033283). High-sensitivity C-reactive protein (hsCRP) was measured ≤3 months before (pre-DOAC hsCRP) and 6±3 months after initiation of DOAC (post-DOAC hsCRP).
Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study.
J Cardiovasc Pharmacol Ther
July 2018
1 Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Background: Although utilization of anticoagulation in patients with atrial fibrillation (AF) has increased in recent years, contemporary data regarding thromboembolism and mortality incidence rates are limited outside of clinical trials. This study aimed to investigate the impact of the direct oral anticoagulants (DOACs) on the clinical outcomes of patients with AF included in the Tasmanian Atrial Fibrillation Study.
Methods: The medical records of all patients with a primary or secondary diagnosis of AF who presented to public hospitals in Tasmania, Australia, between 2011 and 2015, were retrospectively reviewed.
Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS Score ≥ 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?
Drugs Aging
November 2017
Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Objective: Our objectives were to (1) describe the evolution of the underuse of anticoagulants in older people with atrial fibrillation (AF) and a CHADS score ≥ 2 since direct oral anticoagulants (DOACs) were introduced to the market and (2) describe factors associated with this underuse.
Methods: We conducted a retrospective cross-sectional study including geriatric patients admitted during the pre-DOAC (2008-2011) and post-DOAC (2013-2015) periods in an academic hospital in Belgium. Five inclusion criteria were met: age ≥ 75 years, diagnosis of AF, indication for anticoagulation (CHADS score ≥ 2), risk of functional decline (Identification of Seniors At Risk [ISAR] score ≥ 2), and comprehensive geriatric assessment.
Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation.
Am J Cardiol
October 2017
Division of Pharmacy, School of Medicine, University of Tasmania, Tasmania, Australia.
Suboptimal guideline adherence and underuse of anticoagulants in patients with atrial fibrillation (AF) have been reported worldwide. This study aimed to compare anticoagulation practice in Australia during the pre- and postdirect oral anticoagulant (DOAC) eras. Between January 2011 and July 2015, patients with nonvalvular AF (NVAF) admitted to the Royal Hobart Hospital, Tasmania, Australia, were retrospectively reviewed.
View Article and Find Full Text PDFEarly introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation.
J Thromb Thrombolysis
October 2016
USD Stroke Unit, DAI di Neuroscienze, Azienda Ospedaliera Universitaria Integrata, Piazzale Aristide Stefani, 1, 37126, Verona, Italy.
Article Synopsis
- Direct oral anticoagulants (DOACs) show a lower risk of intracranial bleeding compared to warfarin, and this study evaluates the safety of introducing DOACs earlier (1-3 days post-stroke) versus later (4-7 days post-stroke) in stroke patients with non-valvular atrial fibrillation (nVAF).
- The analysis involved 147 nVAF patients, with CT scans assessing intracranial bleeding before and after starting DOACs. Results showed no significant bleeding risk associated with early DOAC introduction, and large infarct size was the only strong predictor of post-DOAC bleeding.
- The findings suggest that starting DOACs early may be safe for selected
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!